产品描述:
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Olomoucine is a cdk inhibitor that acts by competing for the ATP binding site of the kinase. This purine derivative is an inhibitor for CDC2/cyclin B (IC50 = 7 µM), Cdk2/cyclin A (IC50 = 7 µM), Cdk2/cyclin E (IC50 = 7 µM), CDK/p35 kinase (IC50 = 3 µM), and ERK1/p44 MAP kinase (IC50 = 25 µM).{15005} Olomoucine inhibits DNA synthesis in interleukin-2 stimulated T lymphocytes, triggers G1 arrest, and is also used to synchronize cells in G1.{15006} This inhibitor can attenuate astroglial proliferation and glial scar formation, decrease lesion cavity and mitigate functional deficits after spinal cord injury (SCI) in rats.{15004} Administration of olomoucine (3 mg/kg/day) to rats after SCI significantly suppressed microglial proliferation and proinflammatory cytokine expression, reduced tissue edema formation, and attenuated the number of apoptotic neurons.{15004}